Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs CLOMIPHENE CITRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
Treatment of ovulatory dysfunction in women desiring pregnancy,Off-label: male infertility (oligospermia), induction of ovulation in assisted reproductive technology
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Terminal elimination half-life is approximately 5–7 days (120–168 hours) for the active zu-isomer, with a longer half-life for its metabolites. This prolonged half-life leads to accumulation with repeated dosing and sustained clinical effects.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Hepatic metabolism; excreted in feces; active metabolites (possibly enterohepatic recirculation).
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Primarily fecal (approximately 50%), with about 8% renal excretion of unchanged drug and metabolites. Biliary excretion is significant, with enterohepatic recirculation contributing to prolonged elimination.
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 80–90% bound to albumin, with significant binding to other plasma proteins including sex hormone-binding globulin (SHBG).
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Apparent volume of distribution is large, approximately 50–100 L/kg, indicating extensive tissue distribution and accumulation, particularly in the liver and reproductive organs.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
Oral: ~100% absorbed, but bioavailability is difficult to quantify due to extensive first-pass metabolism and enterohepatic cycling; essentially complete systemic exposure after oral administration.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
No specific dose adjustment guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Contraindicated in patients with liver disease or hepatic dysfunction; no Child-Pugh based adjustments available.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Not recommended for use in children; safety and efficacy not established.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Not indicated for use in elderly patients; no specific dosing recommendations.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Should not be used in patients with liver disease or abnormal uterine bleeding of undetermined origin.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Ovarian enlargement/cysts; visual disturbances; multiple pregnancy; ovarian hyperstimulation syndrome; vasomotor symptoms; blurred vision; prolonged use may increase risk of borderline or invasive ovarian tumors.
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Pregnancy; liver disease or history; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement due to polycystic ovary syndrome; hypersensitivity to clomiphene.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
No significant food interactions. Avoid excessive alcohol consumption as it may impair fertility.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and third trimester: no data due to contraindication. Risk of multiple gestation (5-12%) increases risks of preterm labor, low birth weight, and congenital anomalies.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Excreted into breast milk; M/P ratio unknown. Clomiphene may reduce milk production due to anti-estrogenic effects. Because of potential for adverse reactions in nursing infants, women are advised not to breastfeed during treatment.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
No dose adjustments in pregnancy as drug is contraindicated. If pregnancy occurs, discontinue immediately. No pharmacokinetic studies in pregnant women; drug should not be used.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Monitor ovarian size and estradiol levels to reduce risk of ovarian hyperstimulation syndrome (OHSS). Use only in patients with ovulatory dysfunction; rule out pregnancy before each cycle. Limit to 6 treatment cycles due to increased risk of ovarian cancer with prolonged use.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
Take clomiphene citrate exactly as prescribed, typically for 5 days starting on day 3-5 of menstrual cycle.,Ovulation usually occurs 5-10 days after the last dose; have intercourse every other day during this window.,Common side effects include hot flashes, mood swings, and visual disturbances; report persistent visual changes immediately.,Risk of multiple pregnancy (mainly twins) is increased; discuss with healthcare provider.,Avoid use if pregnant, have liver disease, or have abnormal vaginal bleeding.
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs CLOMIPHENE CITRATE, answered by our medical review team.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. CLOMIPHENE CITRATE is a Selective Estrogen Receptor Modulator (SERM) that works by Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and CLOMIPHENE CITRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of CLOMIPHENE CITRATE is: 50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and CLOMIPHENE CITRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. CLOMIPHENE CITRATE is classified as Category A/B. FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.